November 18, 2026, 4:47 pm | Read time: 4 minutes
Semaglutide is currently approved for weight reduction only for those aged twelve and older. However, for younger children, there is now reliable data available for the first time: The Phase 3 study “STEP Young,” published in the New England Journal of Medicine, examines the use of the drug, known as a weight-loss injection, in children aged six to eleven. FITBOOK inquired with two study authors about this.
The double-blind study, in which neither the participants nor the researchers knew who received which drug, involved 167 children aged six to eleven with obesity.1 They received either semaglutide or a placebo in a 2:1 ratio–administered subcutaneously, or under the skin, once a week for a total of 104 weeks. More than 85 percent of the children had Grade II or III obesity at the start of the study. Both groups also received lifestyle counseling.
Significant Decrease in BMI
After 68 weeks, the BMI under semaglutide had decreased by an average of 13.5 percent. In contrast, it increased by 2.7 percent in the placebo group. The effect was particularly evident in the classification of weight: 38 percent of the treated children were no longer considered obese. Their BMI was below the so-called 95th percentile, an age- and gender-dependent threshold for obesity. Under placebo, it was only two percent. After two years, the difference between the groups was nearly 18 percentage points.
“This is a significant study because it is important that children also benefit from scientific and clinical progress,” says Prof. Dr. Antje Körner, a pediatric endocrinologist at the University of Leipzig and co-author of the study.
Why Early Treatment Is Important
Obesity usually does not resolve on its own: About 90 percent of affected children remain obese into adolescence and adulthood. Additionally, health consequences often appear early.
“In this study, about half of the children already had at least one complication,” says Körner–such as metabolic disorders, high blood pressure, or liver diseases. Under semaglutide, these conditions improved significantly: “Almost all children who had prediabetes at the start had normal blood sugar levels by the end.”
However, Körner does not see the medication as a replacement for behavioral therapy. Instead, the drug treatment always builds on a therapy that addresses health behavior and lifestyle.
Study co-author Prof. Dr. med. Martin Wabitsch from the University Hospital Ulm also does not see its use for all children with obesity. It is suitable for “children with pathological, severe obesity for whom the lifestyle training recommended in the guidelines is not effective,” says Wabitsch.
Growth, Bone Age, and Puberty
Special attention was paid to the physical development of the six- to eleven-year-old children. At this age, the question arises whether drug-induced weight reduction affects growth and maturation. The starting point is crucial: Children with obesity often show temporary growth acceleration and are significantly taller than their normal-weight peers.
“This aforementioned growth acceleration was declining in the group with semaglutide,” says the professor. Accordingly, the increase in height was slightly less. “However, all children were still significantly above the average for healthy children with normal weight.”
Bone age, a measure of biological maturity, was accelerated by about two years at the start of the study. During the study, it progressed at about one year per year in both groups. The researchers found no differences in pubertal development between the groups for either girls or boys.
New drug could be more effective than Ozempic for weight loss
New Diet Pill Shows Similar Effects to Ozempic
These Are the Side Effects
The most frequently reported side effect was vomiting. Under semaglutide, it occurred at least once in nearly 70 percent of the children, compared to about 30 percent under placebo. The complaints were particularly common during dose escalation.
“If vomiting occurred, we could reduce the dose again and increase it more slowly,” says Körner. Only one child discontinued the treatment because of this.
Also of interest: The risk of vision loss is nearly five times higher with Wegovy than with Ozempic
Long-term Effects Remain Unclear
After discontinuing semaglutide, the BMI increased again. According to Körner, whether early drug treatment pays off in the long term can only be assessed with further long-term data–”and in both directions.”
Wabitsch also emphasizes the need for ongoing treatment: “Obesity is a chronic disease, like high blood pressure or diabetes, and requires long-term therapy that cannot be discontinued.” Semaglutide is not yet approved for children under twelve.
Besides approval, Wabitsch also sees cost coverage as a hurdle. Even for adolescents aged twelve and older, access in Germany is limited. “The reason for this is that cost coverage by health insurance is not possible,” he explains. For younger children, approval by the European Medicines Agency (EMA) is first required.
Important Note: The study was funded by the pharmaceutical company Novo Nordisk, which markets semaglutide. Employees of the company were also involved in the scientific publication. Additionally, Novo Nordisk financed editorial support for the preparation of the manuscript.